{ "format" : "linked-data-api", "version" : "0.2", "result" : {"_about" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-AnswerDate=2019-06-04&ddpCreated=2019-05-21T17%3A39%3A46.643Z&hansardHeading=Sickle+Cell+Diseases%3A+Health+Services", "definition" : "http://eldaddp.azurewebsites.net/meta/answeredquestions.text?min-AnswerDate=2019-06-04&ddpCreated=2019-05-21T17%3A39%3A46.643Z&hansardHeading=Sickle+Cell+Diseases%3A+Health+Services", "extendedMetadataVersion" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-AnswerDate=2019-06-04&_metadata=all&ddpCreated=2019-05-21T17%3A39%3A46.643Z&hansardHeading=Sickle+Cell+Diseases%3A+Health+Services", "first" : "http://eldaddp.azurewebsites.net/answeredquestions.text?_page=0&min-AnswerDate=2019-06-04&ddpCreated=2019-05-21T17%3A39%3A46.643Z&hansardHeading=Sickle+Cell+Diseases%3A+Health+Services", "hasPart" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-AnswerDate=2019-06-04&ddpCreated=2019-05-21T17%3A39%3A46.643Z&hansardHeading=Sickle+Cell+Diseases%3A+Health+Services", "isPartOf" : "http://eldaddp.azurewebsites.net/answeredquestions.text?min-AnswerDate=2019-06-04&ddpCreated=2019-05-21T17%3A39%3A46.643Z&hansardHeading=Sickle+Cell+Diseases%3A+Health+Services", "items" : [{"_about" : "http://data.parliament.uk/resources/1127755", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1127755/answer", "answerText" : {"_value" : "

It is anticipated that NHS England\u2019s new model for specialised haemoglobinopathy services will be in place by early 2020. The new model is designed to improve access to specialist advice and care for patients, irrespective of where they live.<\/p>

As part of the new service, NHS England is establishing a National Haemoglobinopathy Panel to provide national multidisciplinary oversight. Patients with complex needs, wherever they live, will be able to be referred to the Panel for expert advice on new treatments and approaches to care. The national service specification will also include guidance for the 13 new born bloodspot screening programme laboratories to refer infants found to be positive for sickle cell disease to the 10 new specialised haemoglobinopathy teams. Whilst NHS England commissions the specialised aspect of haemoglobinopathy care, haemoglobinopathy coordinating centres will be encouraged to link with and support community-based services provided through primary care or community teams based within haemoglobinopathy teams.<\/p>

The service specifications for the new specialised haemoglobinopathy teams and the haemoglobinopathy coordinating centres are due to be established in the next month and the associated impact assessment will be published as part of the suite of documents. The equality impact assessment indicates that it will advance the promotion of equality and support the reduction of health inequalities. For example, patients with thalassemia and sickle cell conditions will have equitable access to high quality specialist care and support within specialised commissioned centres irrespective of where in the country they live.<\/p>

Hospital Episode Statistics data is attached, showing finished admission episodes with a primary and a primary or secondary diagnosis of sickle cell disorders by NHS England region of residence and Index of Multiple Deprivation decile in the year 2017-18.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"} } , "answeringMemberConstituency" : {"_value" : "South Ribble"} , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"} , "attachment" : {"_about" : "http://data.parliament.uk/resources/1127755/answer/attachment/1", "fileName" : {"_value" : "Data Table for Combined Diana Johnson PQs (257011) formatted.xlsx"} , "title" : "FAE sickle cell NHS England table"} , "dateOfAnswer" : {"_value" : "2019-06-04", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "256972"} , {"_value" : "256974"} , {"_value" : "257011"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-06-04T16:13:21.707Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-05-21", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Sickle Cell Diseases: Health Services"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment he has made of the effect of NHS England\u2019s planned restructuring of haemoglobinopathy services on (a) equitable access to services, (b) access to the most effective treatments, (c) access to highly specialised care and (d) quality of care in community-based settings for patients with sickle cell disease.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/1533", "label" : {"_value" : "Biography information for Dame Diana Johnson"} } , "tablingMemberConstituency" : {"_value" : "Kingston upon Hull North"} , "tablingMemberPrinted" : [{"_value" : "Diana Johnson"} ], "uin" : "256973"} ], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 1, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]} }